▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Dova Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $28.04.
The current consensus among 0 polled investment analysts is to n/a stock in Dova Pharmaceuticals. This rating has held steady since October 2020, when it changed from a Hold consensus rating.
Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.